Core Viewpoint - Medtide Inc. (泰德医药) successfully listed on the Hong Kong Stock Exchange on June 30, 2025, raising approximately HKD 514 million through the issuance of 16.8 million H-shares, representing 11.85% of total shares post-IPO [3][4]. Group 1: IPO Details - The public offering was oversubscribed by 301.15 times, while the international offering was oversubscribed by 2.43 times [4]. - Two cornerstone investors participated in the IPO, subscribing to approximately 2.565 million shares (USD 10 million), accounting for 15.27% of the global offering and 1.81% of total shares post-IPO [4]. - The final offer price was set at HKD 30.60 per share [3]. Group 2: Shareholder Structure - Dr. Xu Qi, through Qikang International, holds 42.01% of the shares, while Ms. Li Xiangli holds a combined direct and indirect stake of 25.36% [4][5]. - Together, Dr. Xu and Ms. Li control approximately 67.37% of the voting rights in the company [5]. Group 3: Company Overview - Medtide Inc. is a Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in peptides, providing comprehensive services from early discovery to commercial production [5]. - According to Frost & Sullivan, Medtide is one of the most comprehensive peptide-focused CRDMOs globally and ranks as the third largest in terms of sales revenue, with a market share of 1.5% as of 2023 [5]. - As of December 31, 2024, Medtide has a project pipeline that includes 1,217 ongoing CRO projects and 332 ongoing CDMO projects [5]. Group 4: Market Performance - After listing, Medtide's share price reached HKD 31.70, reflecting a 3.59% increase, with a total market capitalization of approximately HKD 4.495 billion [6]. - The stock's trading volume was 6.9414 million shares, with a closing price of HKD 30.60 on the previous day [7].